Tofacitinib extended release - Triastek
Alternative Names: T-19Latest Information Update: 21 Jul 2024
At a glance
- Originator Triastek
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Rheumatoid arthritis
Most Recent Events
- 12 Jun 2024 Pharmacokinetics data from clinical trial in Rheumatoid arthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 28 Aug 2023 T 19 is available for licensing as of 20 Jul 2023. https://www.triastek.com/
- 31 Jul 2023 The NMPA approves IND application for T 19 in Rheumatoid-arthritis, before July 2023 (Triastek website, July 2023)